REGN
Regeneron Pharmaceuticals
4 super-investors hold REGN worth a combined $3.70B. The largest position: Mason Hawkins at 5.0% of their portfolio. This quarter the cohort logged 0 buys and 1 sell on the name. Cohort Conviction Score: 26 — ranked #505 of 724 scored stocks.
Why super-investors own REGN
The dominant fact here is scale rather than breadth: Dodge & Cox's $3.4B position accounts for the overwhelming majority of the cohort's $3.7B combined exposure, making REGN effectively a Dodge & Cox story dressed up as a multi-manager thesis. Mason Hawkins holds the highest concentration at 5.0% of his portfolio ($101M) but trimmed his position in 2026Q1 — the only activity this quarter. Harry Burn carries 3.9% ($117M) and Joel Greenblatt holds a token $37M. Cohort interest has been notably thin and erratic: owner count reached a recent peak of two before retreating, and sits at one across the past three quarters in the data. No manager added or initiated in 2026Q1, signaling that enthusiasm for the name within this cohort is flat to fading.
AI-synthesized from 13F filings. Not investment advice.
Cohort owners over time
2017Q3 → 2026Q1How many of the cohort members held this stock each quarter.
Owners (4) · click any column to sort
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Dodge & Cox Funds | 1.9% | 18q | $3.44B | 4,458,238 |
| 2 | Harry Burn | 3.9% | 3q | $117M | 150,960 |
| 3 | Mason Hawkins | 5.0% | 5q | $101M | 130,662 |
| 4 | Joel Greenblatt | <0.1% | 39q | $37M | 47,687 |
Owners of REGN also hold
Recent activity (1)
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Mason Hawkins | TRIM | 5.0% | -21% | $101M | May 15, 2026 |
Long US equity 13F-HR filings only. CUSIP 75886F107. Not investment advice.